Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziprasidone hydrochloride monohydrate
Drug ID BADD_D02390
Description Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537] Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Indications and Usage In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342]
Marketing Status approved
ATC Code N05AE04
DrugBank ID DB00246
KEGG ID D02100; D01939; D08687
MeSH ID C092292
PubChem ID 60853
TTD Drug ID D0R1JV
NDC Product Code 65841-157; 55111-890
UNII 216X081ORU
Synonyms ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059
Chemical Information
Molecular Formula C21H24Cl2N4O2S
CAS Registry Number 138982-67-9
SMILES C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Akathisia17.01.02.002; 19.06.02.006--
Asthenia08.01.01.001---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dyskinesia17.01.02.006--
Dystonia17.01.03.001---
Extrapyramidal disorder17.01.02.007--
Hypertonia15.05.04.007; 17.05.02.001---
Hypokinesia17.01.02.009---
Muscle twitching15.05.03.005---
Paralysis17.01.04.004---
Somnolence17.02.04.006; 19.02.05.003--
Tremor17.01.06.002--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Respiratory tract infection11.01.08.017; 22.07.07.001---
The 1th Page    1    Total 1 Pages